| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_934053df77400df9844cdedbf3d7c4f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_503a57f1a698ca5b2e4894817042d5a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7e2b9a11a3f71d165e7dd72230437a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a6acb10218c81668aa14204a1a7be2e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d76afe54766502ca7b12aee7e0efe53 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
| filingDate |
2010-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b129263c6fb84d4e76b397c6f369b285
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3889d9ef3fef04c1ec544a266a64151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_530b4f6ab219f174be43856f10be2c8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a9f8e124f421eaf81943a4dff1eea37 |
| publicationDate |
2012-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012129768-A1 |
| titleOfInvention |
Glp-1 analogues and their pharmaceutical salts and uses |
| abstract |
This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity. n n n n n n n n (I) n n n X 1 -X 2 -Glu-Gly-Thr-Phe-Thr-Ser-Asp-X 10 -Ser-X 12 - n n n n n n X 13 -X 14 -Glu-X 16 -X 17 -Ala-X 19 -X 20 -X 21 -Phe-Ile-X 24 - n n n n n n Trp-Leu-X 27 -X 28 -X 29 -X 30 -X 31 -X 32 -X 33 -X 34 -X 35 -X 36 - n n n n n n X 37 -X 38 -X 39 -Lys |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11117946-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022143515-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022143516-A1 |
| priorityDate |
2009-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |